Literature DB >> 18194489

Value of the intravenous and oral glucose tolerance tests for detecting subtle impairments in insulin sensitivity and beta-cell function in former gestational diabetes.

A Tura1, A Mari, T Prikoszovich, G Pacini, A Kautzky-Willer.   

Abstract

OBJECTIVE: Women with former gestational diabetes mellitus (fGDM) often show defects in both insulin sensitivity and beta-cell function but it is not clear which defect plays the major role or which appears first. This might be because fGDM women are often studied as a unique group and not divided according to their glucose tolerance. Different findings might also be the result of using different tests. Our aim was to study insulin sensitivity and beta-cell function with two independent glucose tolerance tests in fGDM women divided according to their glucose tolerance. DESIGN AND PATIENTS: A total of 108 fGDM women divided into normal glucose tolerance (IGT; N = 82), impaired glucose metabolism (IGM; N = 20) and overt type 2 diabetes (T2DM; N = 6) groups, and 38 healthy control women (CNT) underwent intravenous (IVGTT) and oral glucose tolerance tests (OGTT). Measurements Insulin sensitivity and beta-cell function were assessed by both the IVGTT and the OGTT.
RESULTS: Both tests revealed impaired insulin sensitivity in the normotolerant group compared to controls (IVGTT: 4.2 +/- 0.3 vs. 5.4 +/- 0.4 10(-4) min(-1) (microU/ml)(-1); OGTT: 440 +/- 7 vs. 472 +/- 9 ml min(-1) m(-2)). Conversely, no difference was found in beta-cell function from the IVGTT. However, some parameters of beta-cell function by OGTT modelling analysis were found to be impaired: glucose sensitivity (106 +/- 5 vs. 124 +/- 7 pmol min(-1) m(-2) mm(-1), P = 0.0407) and insulin secretion at 5 mm glucose (168 +/- 9 vs. 206 +/- 10 pmol min(-1) m(-2), P = 0.003).
CONCLUSIONS: Both insulin sensitivity and beta-cell function are impaired in normotolerant fGDM but the subtle defect in beta-cell function is disclosed only by OGTT modelling analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18194489     DOI: 10.1111/j.1365-2265.2008.03178.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  TyGIS: improved triglyceride-glucose index for the assessment of insulin sensitivity during pregnancy.

Authors:  Benedetta Salvatori; Tina Linder; Daniel Eppel; Micaela Morettini; Laura Burattini; Christian Göbl; Andrea Tura
Journal:  Cardiovasc Diabetol       Date:  2022-10-18       Impact factor: 8.949

2.  An empirical index of insulin sensitivity from short IVGTT: validation against the minimal model and glucose clamp indices in patients with different clinical characteristics.

Authors:  A Tura; S Sbrignadello; E Succurro; L Groop; G Sesti; G Pacini
Journal:  Diabetologia       Date:  2009-10-30       Impact factor: 10.122

3.  Evaluation of intragastric vs intraperitoneal glucose tolerance tests in the evaluation of insulin resistance in a rodent model of burn injury and glucagon-like polypeptide-1 treatment.

Authors:  Susumu Watada; Yong-Ming Yu; Alan J Fischman; Tomohiro Kurihara; Chuan-An Shen; Ronald G Tompkins; Shawn Fagan
Journal:  J Burn Care Res       Date:  2014 Jan-Feb       Impact factor: 1.845

4.  Routine OGTT: a robust model including incretin effect for precise identification of insulin sensitivity and secretion in a single individual.

Authors:  Andrea De Gaetano; Simona Panunzi; Alice Matone; Adeline Samson; Jana Vrbikova; Bela Bendlova; Giovanni Pacini
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

5.  Progression to type 2 diabetes in women with former gestational diabetes: time trajectories of metabolic parameters.

Authors:  Andrea Tura; Angela Grassi; Yvonne Winhofer; Annamaria Guolo; Giovanni Pacini; Andrea Mari; Alexandra Kautzky-Willer
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

6.  Incretin Effect in Women with Former Gestational Diabetes within a Short Period after Delivery.

Authors:  G Pacini; A Tura; Y Winhofer; A Kautzky-Willer
Journal:  Int J Endocrinol       Date:  2012-04-19       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.